抗血液肿瘤药物的肝损伤  

Liver injury associated with use of anti-hematologic malignancy drugs

作　　者：马玉花[1] 邹亚伟[1] 陈福雄[1] 

机构地区：[1]广州医学院第一附属医院儿科,广东510120

出　　处：《中国临床新医学》2012年第9期898-902,共5页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

基　　金：广东省科技厅社会发展计划项目(编号:2011B031800346)

摘　　要：药物性肝损伤是指由于药物及其代谢产物的毒性作用或机体对药物产生过敏反应从而对肝脏造成损伤。据美国统计,药物从市场撤出的最常见原因是其肝毒性作用,50%的急性肝衰竭由不当用药引起。与其他药物相似,抗肿瘤药物也能引起肝脏从非特异性的生化改变到急慢性肝炎,甚至肝衰竭、肝硬化等。肿瘤患者的化疗方案是基于对患者临床状况和化疗药物相关毒性进行全面评估而选择的,因此,临床医师应对化疗药物肝毒性的特点进行全面了解,旨在预测、防治这些药物严重的不良反应,并最终化疗成功。Drug-induced liver injury is due to the toxic effects of drugs and their metabolites or body allergic reaction to drugs, which cause liver injury. According to the U.S. statistics, the most common reason that drug with- drawal from the market is liver toxicity, and 50% of acute liver failure was caused through improper medication. The antineoplastic agents, similar to other drugs, can cause liver that from non-specific biochemical changes to acute or chronic hepatitis, even liver failure and cirrhosis. Tile selection of a chemotherapeutic regimen for the oneology pa- tient is based on a thorough assessment of potential hazards relating to the patient＇ s clinical condition and the toxici- ties of chemotherapy. Therefore, comprehensive understanding of hepatotoxic manifestations for the most common chemotherapeutic agents is essential, that aims to predict, prevent these severe reactions, and ultimately make chemo- therapy success.

关 键 词：血液肿瘤 药物 肝损伤 

分 类 号：R729[医药卫生—儿科]